ACLY has been proposed as the key enzyme regulating acquired CDDP resistance in ovarian cancer and, therefore, as a suitable novel target for sensitization of ovarian tumours to platinum agents [278,281]. This evidence concerns the gene ACLY and ovarian cancer.